Assessment of Hemodynamic Response in Cardiopulmonary Bypass Graft After Cardiopulmonary Bypass Using Transesophegeal Echocardiography
Information source: Federal University of Juiz de Fora
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cardiopulmonary Bypass Graft
Intervention: epinephrine and levosimendan (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Federal University of Juiz de Fora Official(s) and/or principal investigator(s): Marcello F Salgado Filho, Master, Principal Investigator, Affiliation: National Institute of Cardiology/Ministry of Health
Summary
This is a double blind randomization study, assessing hemodynamic response in patients who
underwent a cardiopulmonary bypass graft (CABG) with cardiopulmonary bypass (CPB) using
intraoperative trasnesophageal echocardiography (TEE) to know what inotropic drug will be
batter to improve the heart function. Epinephrine, milrinone, dobutamine and levosimendan
will be assessment.
Clinical Details
Official title: Assessment and Hemodynamic Response in CABG After Cardiopulmonary Bypass Using Intraoperative Transesophegeal Echocardiography
Study design: Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Systolic and diastolic heart function
Secondary outcome: Mortality after CABAG
Eligibility
Minimum age: 45 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Sinusal ritmus
- EF > 35%
- Elective CABG surgery
Exclusion Criteria:
- No accept
- Severe valvular regurgitation or stenoses
- Chest pain
- Cardiogenic shock
Locations and Contacts
National Institute of Cardiology / Ministry of Health, Rio de janeiro, RJ 3600-100, Brazil
Additional Information
Starting date: February 2012
Last updated: May 29, 2015
|